Eprex in the management of anemia related to lymphoproliferative disorders

Eprex in the management of anemia related to lymphoproliferative disorders

We report results of therapy with recombinant human erythropoietin alpha (Eprex) in patients (pts) with multiple myeloma and chronic lymphocytic leukaemia during chemotherapy. 14pts were included in this study. A level of endogenous erythropoietin, a serum iron binding capacity, and a level of serum...

Full description

Bibliographic Details
Main Authors: P. N. Barlamov, M. E. Golubeva, G. V. Firsova, E. R. Vasilyeva, S. V. Meresiy, O. V. Kanukova, I. V. Klimova, A. A. Shutilev, M. A. Avtomenko, V. V. Shekotov, U. V. Zaychykina
Format: Article
Language:Russian
Published: ABV-press 2022-11-01
Series:Онкогематология
Subjects:
endogenous erythropoietin
anemia
eprex
hemoglobin
polychemotherapy
multiple myeloma
chronic lymphocytic leukaemia
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/624

Internet

https://oncohematology.abvpress.ru/ongm/article/view/624

Similar Items